Associated Papers
Rational design of a covalent ACE2 decoy receptor that broadly neutralizes SARS-CoV-2 variants.
Hino N et al.
Protein Science : a Publication of the Protein Society, 2025
Droplet microfluidic screening to engineer angiotensin-converting enzyme 2 (ACE2) catalytic activity.
Okal EF et al.
Journal of Biological Engineering, 2025
39901286 (PubMed )
Supplement: 13036_2025_482_MOESM3_ESM.xlsx › table_for_paper
Inhibitor screening using microarray identifies the high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection and vaccination.
Zhang X et al.
Theranostics, 2022
35401825 (PubMed )
Supplement: thnov12p2519s1.pdf
Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries.
Wang R et al.
Genomics, 2021
34004284 (PubMed )
Supplement: mmc2.pdf
Mutations in the SARS-CoV-2 spike protein modulate the virus affinity to the human ACE2 receptor, an in silico analysis.
Ortega JT et al.
Excli Journal, 2021
A Computational Approach to Evaluate the Combined Effect of SARS-CoV-2 RBD Mutations and ACE2 Receptor Genetic Variants on Infectivity: The COVID-19 Host-Pathogen Nexus.
Ashoor D et al.
Frontiers in Cellular and Infection Microbiology, 2021
34434902 (PubMed )
Supplement: DataSheet_4.xlsx › Sheet1
The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity.
Li Q et al.
Cell, 2020
Select a paper to view details